The investigators undertook a study in which they retrospectively evaluated the presence and amount of small HRF in the eyes of patients with different macular atrophic phenotypes.
Oral gildeuretinol demonstrated a clinically meaningful reduction in the geographic atrophy lesion growth rate at 24 months, supporting additional clinical development. SAGA topline data has been accepted as a late breaker at the 128th annual meeting of the American Academy of Ophthalmology, being held October 18-21 in Chicago.
According to the company, the pilot study showed procedural feasibility of ophthalmic artery angioplasty in the treatment of vascular lesions associated with geographic atrophy (GA).